Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sudeep Dhillon

Endocrinology, Diabetes & Metabolism Pennington, NJ Medical Doctor

NPI 1780904094 CMS profile 353143

2 Capital Way Ste 315, Pennington, NJ 08534

Open in the dashboard

General payments

$44,654

1,117 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sudeep Dhillon of Pennington, NJ is reported in the CMS Open Payments database as having received $44,654 across 1,117 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,024 132
2024 General $1,701 110
2023 General $1,744 132
2022 General $3,496 213
2021 General $7,306 182
2020 General $7,160 168
2019 General $21,223 180

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sudeep Dhillon
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Sudeep Dhillon were reported at $2,024. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Sudeep Dhillon Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $21,223 $494 $123–$2,253 $163
2020 $7,160 $335 $85–$1,841 $114
2021 $7,306 $398 $88–$1,981 $132
2022 $3,496 $364 $88–$1,568 $149
2023 $1,744 $420 $113–$1,614 $160
2024 $1,701 $440 $121–$1,646 $164
2025 $2,024 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $32,205 92 payments
  2. Novo Nordisk Inc $2,722 373 payments
  3. Lilly USA, LLC $1,429 108 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,078 76 payments
  5. Amneal Pharmaceuticals LLC $833 52 payments
  6. Mannkind Corporation $454 32 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $442 31 payments
  8. Amgen Inc. $435 32 payments
  9. Kowa Pharmaceuticals America, Inc. $403 30 payments
  10. Amarin Pharma Inc. $314 24 payments
  11. Other $4,341 267 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $28,500 19 payments
  2. Food and Beverage $14,894 1,083 payments
  3. Travel and Lodging $1,178 8 payments
  4. Education $82 7 payments
Products named General payments · program years 2019–2025
  1. FARXIGA $32,205 92 payments
  2. Ozempic $1,838 283 payments
  3. RYBELSUS $1,792 273 payments
  4. UNITHROID $833 52 payments
  5. JARDIANCE Diabetes $683 50 payments
  6. JARDIANCE Diabetes $603 43 payments
  7. TRULICITY $599 45 payments
  8. MOUNJARO $466 36 payments
  9. AFREZZA $454 32 payments
  10. Kerendia $442 31 payments
  11. Other $9,355 672 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 79 drugs

Part D claims

5,767

Median for Endocrinology: 1,959

Drug cost

$3,322,534

Median for Endocrinology: $890,201

Branded share of claims

58.8%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 543 $963,736
Mounjaro Tirzepatide Brand 230 $392,664
Jardiance Empagliflozin Brand 148 $177,410
Tresiba Flextouch U-200 Insulin Degludec Brand 203 $170,744
Farxiga Dapagliflozin Propanediol Brand 184 $167,849
Synjardy Xr Empagliflozin/Metformin Hcl Brand 125 $137,953
Rybelsus Semaglutide Brand 62 $137,454
Janumet Xr Sitagliptin Phos/Metformin Hcl Brand 129 $135,950
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 129 $121,097
Januvia Sitagliptin Phosphate Brand 79 $104,011

The 10 drugs with the highest cost, of 79 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$93,073

Of which drugs: $3,490

Medicare patients

286

Average age 73

Services billed

1,421

163 women, 123 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 74%
Arthritis 47%
Ischemic heart disease 36%
Chronic kidney disease 31%
Depression 20%
Osteoporosis 19%
Atrial fibrillation 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 40 40 $2,867
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 24 62 $57

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$249 148 —
UNITHROID
$212 — —
LEQVIO
$114 — —
MOUNJARO
$99 230 —
RYBELSUS
$84 62 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

1,117 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record